|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
24,730,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Equillium is a clinical-stage biotechnology company to develop therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Co.'s pipeline is focused on developing itolizumab (EQ001), EQ101 and EQ102 as potential disease modifying treatments for multiple severe immuno-inflammatory disorders. Co. has active clinical development programs for itolizumab (EQ001) for the treatment of acute graft-versus-host disease and lupus/lupus nephritis. Co. also has a proprietary product discovery platform that it can utilize to design peptides to target and inhibit multiple cytokines that are involved in validated biological and disease pathways.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
12,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$32,410 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tom Penny |
Principal Accounting Officer |
|
2024-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,857 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2023-12-08 |
4 |
A |
$0.58 |
$5,107 |
D/D |
8,805 |
58,913 |
|
- |
|
Zedelmayer Christine |
Sr. Vice President and COO |
|
2023-12-08 |
4 |
A |
$0.58 |
$5,106 |
D/D |
8,804 |
135,246 |
|
- |
|
Rothman Joel |
Chief Development Officer |
|
2023-12-08 |
4 |
A |
$0.58 |
$5,106 |
D/D |
8,804 |
58,150 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2023-06-09 |
4 |
A |
$0.56 |
$8,400 |
D/D |
15,000 |
50,108 |
|
- |
|
Zedelmayer Christine |
Sr. Vice President and COO |
|
2023-06-09 |
4 |
A |
$0.56 |
$8,400 |
D/D |
15,000 |
126,442 |
|
- |
|
Rothman Joel |
Chief Development Officer |
|
2023-06-09 |
4 |
A |
$0.56 |
$8,400 |
D/D |
15,000 |
49,346 |
|
- |
|
Rothman Joel |
Chief Development Officer |
|
2022-12-09 |
4 |
A |
$1.19 |
$4,547 |
D/D |
3,821 |
34,346 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2022-12-09 |
4 |
A |
$1.19 |
$5,288 |
D/D |
4,444 |
35,108 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2022-08-29 |
4 |
AS |
$2.83 |
$19,810 |
I/I |
(7,000) |
77,720 |
|
- |
|
Zedelmayer Christine |
Sr. Vice President and COO |
|
2022-06-10 |
4 |
A |
$1.85 |
$16,711 |
D/D |
9,033 |
111,442 |
|
- |
|
Rothman Joel |
Chief Development Officer |
|
2022-06-10 |
4 |
A |
$1.85 |
$11,551 |
D/D |
6,244 |
30,525 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2022-06-06 |
4 |
AS |
$2.52 |
$12,600 |
I/I |
(5,000) |
84,720 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2022-04-04 |
4 |
AS |
$3.18 |
$25,440 |
I/I |
(8,000) |
89,720 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2021-12-10 |
4 |
A |
$2.35 |
$13,125 |
D/D |
5,585 |
23,296 |
|
- |
|
Rothman Joel |
Chief Development Officer |
|
2021-12-10 |
4 |
A |
$2.35 |
$3,032 |
D/D |
1,290 |
24,281 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2021-12-01 |
4 |
AS |
$5.08 |
$25,402 |
I/I |
(5,000) |
97,720 |
|
- |
|
Zedelmayer Christine |
Sr. Vice President and COO |
|
2021-11-16 |
4 |
AS |
$5.49 |
$62,715 |
D/D |
(11,434) |
102,409 |
|
- |
|
Zedelmayer Christine |
Sr. Vice President and COO |
|
2021-11-16 |
4 |
OE |
$2.45 |
$57,168 |
D/D |
23,334 |
109,759 |
|
- |
|
Connelly Stephen |
Chief Scientific Officer |
|
2021-10-06 |
4 |
AS |
$7.01 |
$56,706 |
D/D |
(8,092) |
993,000 |
|
- |
|
Connelly Stephen |
Chief Scientific Officer |
|
2021-10-06 |
4 |
OE |
$2.80 |
$33,626 |
D/D |
8,092 |
995,467 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2021-09-27 |
4 |
AS |
$6.74 |
$53,924 |
I/I |
(8,000) |
102,720 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2021-07-27 |
4 |
AS |
$5.72 |
$28,585 |
I/I |
(5,000) |
110,720 |
|
- |
|
Zedelmayer Christine |
Sr. Vice President and COO |
|
2021-06-10 |
4 |
A |
$2.35 |
$21,225 |
D/D |
9,032 |
90,509 |
|
- |
|
Keyes Jason A |
Chief Financial Officer |
|
2021-06-10 |
4 |
A |
$2.35 |
$13,007 |
D/D |
5,535 |
17,711 |
|
- |
|
51 Records found
|
|
Page 1 of 3 |
|
|